IRRAS Appoints Medical Technology Leader C. Lance Boling as Vice President, Product Development

"I am excited to welcome Lance as a member of the IRRAS executive management team as we expand our commercial footprint and advance our IRRAflow™ technology," said Kleanthis G. Xanthopoulos, Ph.D., Chairman and CEO of IRRAS.  "Lance has very impressive credentials – in addition to his deep medical device development expertise, he also brings valuable manufacturing and operations experience that will greatly enhance our ability to transform the way strokes and brain hematomas are treated."

"Each year in the U.S. and EU, approximately two million people suffer strokes and almost three hundred thousand have a hemorrhagic stroke, with almost half of these instances ending in death. Unfortunately, the current available medical devices cannot address the complications that lead to death and the need for innovation in this field is urgent," said C. Lance Boling, Vice President, Product Development of IRRAS.  "Because of this, I am extremely pleased to join the IRRAS team to combat this global health issue. We plan to aggressively expand and advance our core IRRAflow™ technology to provide patients, physicians and payors with an intelligent solution for the management of strokes and brain hematomas."

Prior to joining IRRAS, Mr. Boling was Director of Nano Technology Development at Abbott Laboratories where he was responsible for leading numerous development efforts from inception through commercialization.  Before Abbott, Mr. Boling held leadership positions at Nanostim, Nevro Corporation, NeuroPace, Inc., and Autonomic Technology.  Mr. Boling holds a BA in Business Management from the University of Phoenix and has participated in Post Graduate studies in Manufacturing Technology at Stanford University. He holds over 40 pioneering patents - granted and pending in the medical device industry - and is a regular guest lecturer on product development at local universities and high schools.

About IRRAflow™

IRRAS has developed and commercialized a revolutionary catheter device stemming from its core IRRAflow™ technology that addresses the complications associated with the occurrence of hemorrhagic stroke. According to the WHO, there are 15 million stroke patients annually and complications from these strokes result in more than 6 million annual deaths, almost 1 every 10 seconds.  Currently available devices do not address the complications that lead to death because they do not prevent occlusion (or blockage) in the catheter during treatment and they do not accurately monitor intracranial pressure (ICP).  IRRAS' clinical strategy is to provide a transformative solution for stroke and hematoma patients with less invasiveness and more efficacy, through the integration of aspiration, targeted infusion and intracranial pressure monitoring in a single robust device.  

About IRRAS

IRRAS AB is a commercial-stage medical technology company formed to develop and commercialize breakthrough devices for a broad range of brain pathology therapeutic applications and procedures. IRRAflow™ is the company's flagship commercial medical device that provides intelligent, dynamic control of CNS fluids to address the complications associated with the occurrence of hemorrhagic stroke. With its unique product portfolio, protected by key intellectual property patents and patent applications, IRRAS is well-positioned to improve patient outcomes and establish a leadership position in the medical device market. IRRAS is operational in Germany and La Jolla, CA, USA with corporate headquarters in Stockholm, Sweden. For more information, please visit www.irras.com.

Contact:
Amy Conrad
1-858-366-3243
[email protected]

SOURCE IRRAS

Related Links

http://www.irras.com